In the United States alone there will be approximately 140 000 cases of lung cancer during 1987. Functionally, these diseases are divided into tumors of the non-small cell (NSCL) and small cell (SCLC) varieties. The former category includes squamous cell adenocarcinoma and large cell anaplastic tumors and the latter includes small cell anaplastic carcinoma, all defined by light microscopy. This functional classification is based upon each category’s distinctive clinical biology, i.e., (a) the potential for surgical curability of NSCL; (b) the propensity of SCLC to widespread dissemination; and (c) the relative responsiveness or unresponsiveness of SCLC and NSCL to existing cytotoxic modalities.
KeywordsAdenocarcinoma Interferon Doxorubicin Cyclophosphamide Alkaloid
Unable to display preview. Download preview PDF.
- 2.Mountain CF (1986) A new international staging system for lung cancer. Chest 89: 225SGoogle Scholar
- 4.Comis RL (1987) Chemotherapy of small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds) Principles and practice of oncology update, vol 1. Lippincott, Philadelphia, p 7Google Scholar
- 6.Einhorn L, Greco FA, Cohen H, Birch R (1987) Late consolidation with cisplatin plus VP-16 (PVP16) following induction chemotherapy with cyclophosphamide, adriamycin and vincristine (CAV) in limited small cell lung cancer (SCLC): a Southeastern Cancer Study Group ( SECSG) random prospective study. Proc Am Soc Clin Oncol 6: 166Google Scholar